bioAffinity Technologies, Inc.: HRT FINANCIAL LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
HRT Financial LP disclosed a stake exceeding 5% in bioAffinity Technologies Inc. via a Schedule 13G filing with the SEC (accession 0001475597-26-000255). The exact share count and percentage were not specified in the filing summary. The disclosure signals that the quantitative trading firm has built a position large enough to trigger passive-investor reporting requirements. Investors will watch for further 13G amendments or 13D filings that could indicate a shift from passive to activist intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
HRT FINANCIAL LP, bioAffinity Technologies, Inc.